l 近年はスライドタイプの資料が多いため、今回はパワポを念頭におきます – パワポ以外のスライド型アプリーKeynote、google Slide – 経験的にはパワポのシェアが圧倒的 l ただし“0から学ぶパワポ講座”ではない事はご了承下さい l また、今日聞いただけでは身につかない事もご理解頂けますと幸いです
it would also replace β to some extent due to its higher F lowering efficacy 原則5 図表は分かりやすさを重視する 例1-文字が多すぎる F lowering efficacy with low Risk of Hypoglycemia l “I would like to use AIV as first line for mild patients since it does not cause hypoglycemia. I may start to use AIV instead of R or β-Z. Especially for obese patients ” (KE specialist, University HP) l AIV will replace R especially for milder obese patients l Ease of use as well as efficacy in mild patients will drive switch from β-Z Evaluation Points Key Implications Once Daily Dosage ReZmen in PPG Treatment Protection on Pancreas High Price IsRes Side Effect Concerns Comments l “Having better compliance in fewer # of dosage is good, if efficacious” (KE specialist, HP) l “If AIV efficacy is as strong as R, I will use AIV instead. I am concerned with how R put strain on pancreas (KE specialist, HP)” l “Although being higher than R, price comparable to β-Z are not much of a concern if compared to inRlin” (KE specialist, HP) l “Low side effect profile will make AIV as good add- on drug among Q” (KE specialist, University HP) l “Need to BC carefully for longer term on side effect of AIV influencing other A receptors” (KE specialist, University HP) l AIV will replace β-Z in non-specific patient types due to advantage in compliance l AIV will replace R in wide patient types, due to resolving physicians' concerns on R in putting strain on pancreas, especially for milder patients l Expected high pricing of AIV (at 200 JPY per tablet) would not be a barrier for Rx l AIV’s good side effect profile will encourage wide replacement of add-on agents l But AIV impact will not rocket due to long term side effect concerns, especially on effecting other A receptors Source: Physician Interview